NCT03308721View on ClinicalTrials.gov

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC9204-1177 A 1.0 mg/mL

"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."

DRUG

PLACEBO

Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.

Trial Locations (1)

66212

Novo Nordisk Investigational Site, Overland Park

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03308721 - Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity | Biotech Hunter | Biotech Hunter